Condition
Fatty Liver Disease
Fatty liver disease is when extra fat builds up in liver cells, often with excess weight and insulin resistance, and can inflame the liver. Retatrutide, a triple hormone agonist, has the strongest evidence, and liver fat fell by roughly 82 to 86 percent in a 48-week trial, with about nine in ten people reaching normal levels. That trial was mid-stage and included only 98 people, so larger, longer studies are still needed.
Sources: PMID 38858523
- Updated
- How we grade
- 61 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 1
No supplement studies yetWe haven’t found supplement studies for Fatty Liver Disease. The medicines and peptides studied for it are listed below.
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Liver Fat Reduction Phase 2a MASLD (n=98): 82-86% relative reduction in liver fat at 48 weeks with 8-12mg. 89-93% achieved normal liver fat (<5%). Driven by glucagon receptor activation promoting hepatic lipid oxidation. | Improves (the measure goes down) | Large effect | 16 studies | |||
Studies that measured liver fat reduction
| ||||||
Key findings
- Liver Fat ReductionImproves (the measure goes down)
Studies cited
61 studies from PubMed
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
- Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
- What is the pipeline for future medications for obesity?
- Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
- Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.
- Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
- Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
- Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
- The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
- Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease.
- Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.
- Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
- Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
- Emerging pharmacotherapies for obesity: A systematic review.
- The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
- Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.
- Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.
- Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
- Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
- Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
- Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.
- Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
- The power of three: Retatrutide's role in modern obesity and diabetes therapy.
- At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
- Gut hormones and appetite regulation.
- Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.
- The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
- Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- Triple G Agonists - A Home Run for Obesity?
- GLP-1 receptor agonists for treatment of obesity: Efficacy and safety considerations
- Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
- Retatrutide showing promise in obesity (and type 2 diabetes).
- Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
- Retatrutide: a triple incretin receptor agonist for obesity management.
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial